title: High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center.
authors.forename: Stephanie B
authors.initials: SB
authors.lastname: Tsai
authors.forename: David C
authors.initials: DC
authors.lastname: Seldin
authors.forename: Karen
authors.initials: K
authors.lastname: Quillen
authors.forename: John L
authors.initials: JL
authors.lastname: Berk
authors.forename: Frederick L
authors.initials: FL
authors.lastname: Ruberg
authors.forename: Hans
authors.initials: H
authors.lastname: Meier-Ewert
authors.forename: J Mark
authors.initials: JM
authors.lastname: Sloan
authors.forename: Gheorghe
authors.initials: G
authors.lastname: Doros
authors.forename: Kathleen T
authors.initials: KT
authors.lastname: Finn
authors.forename: Martha
authors.initials: M
authors.lastname: Skinner
authors.forename: Vaishali
authors.initials: V
authors.lastname: Sanchorawala
mesh_terms: D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000401:mortality* / Q000628:therapy*; D002423:Cause of Death; D004305:Dose-Response Relationship, Drug; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology / Q000401:mortality; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006801:Humans; D007147:Immunoglobulin Light Chains; D008558:Melphalan / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D009026:Mortality / Q000639:trends*; D019653:Myeloablative Agonists / Q000008:administration & dosage / Q000009:adverse effects; D062606:Tertiary Care Centers / Q000706:statistics & numerical data; D013997:Time Factors
chemical_list: D007147:Immunoglobulin Light Chains; D019653:Myeloablative Agonists; D008558:Melphalan